Comparative treatment with hyperbaric oxygen therapy in a model of systemic loxoscelism in rats

Document Type : Original Article


Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, México City, México


Objective(s): Spiders of the Loxosceles genus, known as violin spiders, produce venom with dermonecrotic and systemic effects, as it is a species widely distributed in the world, its study represents a high medical relevance. Systemic loxoscelism, which occurs in 1 in 5 cases and is the most frequent in children, can be fatal, so the study of effective therapy is of great relevance. In the present study, we compared different therapeutic options to mitigate the systemic effects of Loxosceles boneti venom in a model in which prepubertal rats were used.
Materials and Methods: A model of systemic intoxication by L. boneti venom was provoked in male Wistar rats. Study groups were formed: healthy control, with venom and untreated control, treatment with N-acetylcysteine, and/or hyperbaric oxygenation therapy. Subsequently, pathological analysis of the kidney and lung was performed. The oxidant-antioxidant response was evaluated, and molecular analysis of the COX-1 and COX-2 enzymes was performed.
Results: Regenerative changes were observed at the cellular level in both treatments, being more noticeable in the HBO group. The anti-oxidant response was outstanding in the same group. 
Conclusion: Both treatments offer considerable benefits, however; further studies are needed to provide adequate therapeutics.


1. Vetter RS, Isbister GK. Medical aspects of spider bites. Annu Rev Entomol 2008;53:409-429.
2. Duncan R.P, Rynerson MR, Ribera C, Binford GJ. Diversity of Loxosceles spiders in Northwestern Africa and molecular support for cryptic species in the Loxosceles rufescens lineage. Mol Phylogenet Evol 2010; 55: 234–248. 
3. Ramos R, Gabriel H, Méndez DJ. Necrotic Araneism. A Review of the Loxosceles Genus. I. General aspects, distribution and venom composition. Adv Environ Biol 2008;2:9-19.
4. Valdez-Mondragón A, Cortez-Roldán MR, Juárez-Sánchez AR, Solís-Catalán KP. A new species of Loxosceles Heineken & Lowe (Araneae, Sicariidae), with updated distribution records and biogeographical comments for the species from Mexico, including a new record of Loxosceles rufescens (Dufour). ZooKeys 2018;802: 39-66.
5. Fernandes P, Junqueira de Azevedo I, Goncalves de Andrade R, van den Berg C, Ramos C. Molecular cloning and expression of a functional dermonecrotic and haemolytic factor from Loxosceles laeta venom. Biochem Biophys Res Commun 2021:298:638-645.
6. Swanson DL, Vetter RS. Loxoscelism. Clin Dermatol 2006:24:213-221.
7. Nag A, Datta J, Das A, Agarwal AK, Sinha D, Mondal S, Ete T, Chakraborty A, Ghosh S. Acute kidney injury and dermonecrosis after Loxosceles reclusa envenomation. Indian J Nephrol 2014; 24: 246-248. 
8. Da Silva PH, da Silveira RB, Appel MH, Mangili OC, Gremski W, Veiga SS. Brown spiders and loxoscelism. Toxicon 2004;44:693-709. 
9. Nguyen N,  Pandey M. Loxoscelism: Cutaneous and hematologic manifestations. Adv Hematol 2019; 2019: 4091278.
10. Karim-Silva S, Becker-Finco A, Jiacomini IG, Boursin F, Leroy A, Noiray M, et al. Loxoscelism: Advances and challenges in the design of antibody fragments with therapeutic potential. Toxins 2020; 12: 256.
11. Pauli I, Puka J, Gubert IC, Minozzo JC. The efficacy of antivenom in loxoscelism treatment. Toxicon 2006; 48:123-137.
12. Maynor ML, Moon RE, Klitzman B, Fracica PJ, Canada A. Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy. Acad Emerg Med 1997;4:184–192.
13. Cetinkaya A, Aydin K, Sirakaya HA, Yilmaz R. A loxoscelism case received therapeutic   apheresis   and   hyperbaric   oxygen   therapy. Saudi Med J 2020; 41:1364-1368. 
14. Heyboer M, Sharma D, Santiago W, Mc Culloch N. Hyperbaric oxygen therapy: Side effects defined and quantified. Adv Wound Care (New Rochelle). 2017;6:210-224.
15. Santus P, Corsico A, Solidoro P, Braido F, Di Marco F, Scichilone N. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD 2014;11:705-717.
16. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. Medicine 2018;97:e13087. 
17. Tambourgi DV, Petricevich VL, Magnoli FC, Assaf SL, Jancar S, Dias Da Silva W. Endotoxemic-like shock induced by Loxosceles spider venoms: Pathological changes and putative cytokine mediators. Toxicon 1998;36:391-403.
18. Lopes PH, Squaiella-Baptistão CC, Marques M, Tambourgi DV. Clinical aspects, diagnosis and management of Loxosceles  spider envenomation: Literature and case review. Arch Toxicol 2020; 94:1461–1477. 
19. Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al. Disseminated intravascular coagulation: An update on pathogenesis, diagnosis, and therapeutic strategies. Clin Appl Thromb Hemost 2018;24:8S-28S.
20. McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model. Clinical Lab Sci 2007; 20:99-105.
21. Ershad M, Naji A, Vearrier D. N Acetylcysteine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [Updated 2022 Jun 27] Available from:
22. Dias-Lopes C, Felicori L, Guimarães G, Gomes ER, Roman-Campos D, Duarte H, et al. Cardiotoxic effects of Loxosceles intermedia spider venom and   the   recombinant   venom   toxin rLiD1. Toxicon 2010; 56:1426–1435.
23. Lucato RV, Abdulkader RC, Barbaro KC, Mendes GE, Castro I, Baptista MA, et al. Loxosceles gaucho venom-induced acute kidney injury: in vivo and in vitro studies. PLoS Negl Trop Dis 2011;5:e1182. 
24. Yamanel L, Kaldirim U, Oztas Y, Coskun O, Poyrazoglu Y, Durusu M, et al. Ozone therapy and hyperbaric oxygen treatment in lung injury in septic rats. Int J Med Sci 2011;8: 48-55.
25. Hołyńska-Iwan I, Wróblewski M, Olszewska-Słonina D, Tyrakowski T. The application of N-acetylcysteine in optimization of specific pharmacological therapies. Pol Merkur Lekarski 2017;43:140-144.
26. Solmazgul E, Uzun G, Cermik H, Atasoyu EM, Aydinoz S, Yildiz S. Hyperbaric oxygen therapy attenuates renal ischemia/reperfusion injury in rats. Urol Int 2007;78:82–85.
27. Hunt TK, Zederfeldt B, Goldstick TK. Oxygen and healing. Am J Surg 1969;118: 521-525.
28. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility. Expert Opin Biol Ther 2008;8:1955–1962.
29. Spapen H. N-acetylcysteine in clinical sepsis: A difficult marriage. Critical care (London, England) 2004;8:229–230.
30. Roca-Ferrer J, Pujols L, AgustI C, Xaubet A, Mullol J, Gimferrer JM, C Picado. Cyclooxigenase- 2 levels are increased in the lung tissue and bronchial tumors of patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2011;12:584-589.
31. Hoffer E, Baum Y, Nahir AM. N-Acetylcysteine enhances the action of anti- inflammatory drugs as   suppressors   of  prostaglandin production in monocytes. Mediators Inflamm 2002;11:321-323.